# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN
- Date: 2026-04-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delia Marchand, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Biopsy result and gynecologic oncology consultation. **S**

## History of present illness

Ms. Radner returns eight days after her first visit. The transvaginal ultrasound the next day showed solid and cystic masses in both ovaries with ascites; CT of the chest, abdomen and pelvis the day after that showed omental and peritoneal disease without spread to the liver, lungs or lymph nodes; and an ultrasound-guided core biopsy of the omentum two days later shows high-grade serous carcinoma of Mullerian origin. Dr. Varghese of gynecologic oncology saw her this morning. The bloating and early fullness are the same; she is eating small meals and has had no vomiting, and her bowels move every day. She says she is frightened but relieved to have an answer within a week. She had genetic counseling this afternoon. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Diagnosis | High-grade serous carcinoma of both ovaries with omental and peritoneal spread; clinical FIGO stage IIIC |
| Imaging | Ultrasound: bilateral complex masses, ascites. CT: omental caking, a right diaphragm nodule, no liver, lung or nodal disease |
| Symptoms | Bloating and early fullness unchanged; no vomiting or bowel obstruction |
| Coordination | Gynecologic oncology seen today; surgery planned in one week; genetic counseling done |
| Her questions | Whether surgery can remove it all, and what the genetic test means for her family |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever or night sweats; weight steady |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Bloating and early fullness; no vomiting; bowels open daily |
| Genitourinary | Positive | Passing urine more often; no bleeding |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Frightened and tearful at times; PHQ-9 7 and GAD-7 8; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 96 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 58.9 kg; BMI 23 kg/m². All vital signs are synthetic.

PHQ-9: 7; GAD-7: 8. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| General | Tired but composed; weight 58.9 kg; blood pressure 122/78, pulse 96 |
| Abdomen | Distended with shifting dullness; firm fullness in the upper abdomen consistent with the omental disease; non-tender; biopsy site clean |
| Pelvic | Examined with Dr. Varghese: fixed, irregular masses in both adnexa, larger on the right; cervix normal; no nodularity of the rectovaginal septum |
| Lymph nodes | No supraclavicular, axillary or inguinal nodes |
| Extremities | No leg swelling |
| Psychiatric | Anxious, tearful briefly, organized; humor intact |

All examination findings are synthetic. **S**

## Assessment and plan

1. **High-grade serous carcinoma of both ovaries, clinical FIGO stage IIIC** (C56.3). Advanced ovarian cancer diagnosed eight days after she first described the symptoms, because the symptom index, the examination, the CA-125 of 1240 with a normal CEA, and the ultrasound were acted on at once. The disease is in the pelvis, omentum, peritoneum and right diaphragm, with no disease in the liver, lungs or lymph nodes on CT. Dr. Varghese judges that all visible disease can probably be removed and recommends primary cytoreductive surgery in one week, then six cycles of carboplatin and paclitaxel. Her fitness for surgery is good; albumin 3.6 g/dL. **S**
   - Primary cytoreductive surgery with Dr. Varghese in one week.
   - Hepatitis B, hepatitis C and HIV tests drawn today, before chemotherapy.
   - Germline multigene panel sent today after genetic counseling; tumor testing for BRCA1, BRCA2 and homologous recombination deficiency on the surgical specimen.
   - Enoxaparin for four weeks after surgery.
   - Urine pregnancy test negative today.
2. **Peritoneal and omental metastases with ascites** (C78.6). Moderate ascites causing the bloating and early fullness; no need for drainage before surgery. **S**
   - Small frequent meals and protein drinks before surgery.
3. **Persistent bloating, early fullness and pelvic pain with an adnexal mass** (R19.00). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.
4. **Family history of ovarian cancer in three relatives** (Z80.41). Ovarian cancer in three relatives and Ashkenazi Jewish ancestry. Germline testing is recommended for every woman with epithelial ovarian cancer, whatever the family history; here the history adds weight. The counselor explained that a variant found in her would allow her blood relatives to be offered testing, and that a negative result would not end their need for advice, because of the family history. **S**
   - Germline multigene panel sent today.
   - Results with the genetic counselor at the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Ovarian cancer symptom index | At presentation | Up to date | Positive at the first visit: bloating, early fullness and pelvic pain on most days for about four weeks |
| Imaging | Transvaginal ultrasound | At presentation with a pelvic mass | Up to date | Done the day after the first visit: bilateral solid and cystic adnexal masses with blood flow and ascites (O-RADS 5) |
| Imaging | CT of the chest, abdomen and pelvis with contrast | Before primary treatment | Up to date | Omental caking, a 1.2 cm right diaphragm nodule and pelvic peritoneal nodules; no liver, lung or lymph node disease; no pleural effusion |
| Laboratory | Tissue diagnosis | Before treatment, by biopsy or at surgery | Up to date | Omental core biopsy: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant |
| Laboratory | CA-125 and CEA | At diagnosis | Up to date | CA-125 1240 U/mL and CEA 1.6 ng/mL at the first visit; the ratio points to an ovarian rather than a bowel primary |
| Laboratory | Blood count, kidney and liver function before surgery | Within 30 days before surgery | Up to date | From the first visit: hemoglobin 12.4 g/dL, platelets 412, creatinine 0.72 mg/dL, albumin 3.6 g/dL |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody, and HIV drawn today |
| Referral | Genetic counseling | At diagnosis of epithelial ovarian cancer | Completed today | Pedigree taken and consent given |
| Laboratory | Germline multigene panel | Once, at diagnosis, for every woman with epithelial ovarian cancer | Ordered | BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes; result in about three weeks |
| Laboratory | Tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency | On the surgical specimen, before the maintenance decision | Due | To be sent from the operation next week |
| Referral | Gynecologic oncology | Before any surgery for suspected ovarian cancer | Completed today | Seen this morning; recommendations in the consultation note |
| Medication safety | Thromboprophylaxis after cancer surgery | From surgery for four weeks | Due | Enoxaparin 40 mg daily for 28 days planned after the operation |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 8, mild, with fear about the diagnosis; no thoughts of self-harm |
| Self-management | Psychosocial support and information | At diagnosis and throughout | Completed today | Plain explanation of the diagnosis and plan with written information; she chose who would be told; details of a cancer support community group given |

## Goal progress

- Tissue diagnosis and gynecologic oncology plan within two weeks of presentation. Outcome by 2026-04-14: Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day. **S**
- Cytoreductive surgery with no visible residual disease within three weeks of diagnosis. In progress; target 2026-05-12. **S**
- Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week. In progress; target 2026-09-15. **S**
- Germline and tumor genetic results available before the maintenance decision. In progress; target 2026-09-15. **S**
- PHQ-9 below 10 throughout treatment, with a peer-support connection. In progress; target 2026-09-15. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026), National Comprehensive Cancer Network
- Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020), American Society of Clinical Oncology
- Goff BA, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221-227 (2007), Cancer (American Cancer Society)
- Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk (2017), American College of Obstetricians and Gynecologists (Obstetrics and Gynecology)
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023), American Society of Clinical Oncology
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020), American Society of Clinical Oncology
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Surgery in one week with Dr. Varghese. Primary care review three weeks after surgery, on the first chemotherapy day, with the pathology and genetic results. Call for vomiting, inability to eat, breathlessness, or leg swelling. **S**
- Next scheduled visit 2026-05-12: review three weeks after cytoreductive surgery: pathology, genetic results, and the first cycle of chemotherapy. **S**
